Ann: Opthea Completes COAST Final Week 52 Patient Visit, page-4

Tremendous milestone achieved. We are at the pointy end now; the culmination of many years of hard work and dedication by some of the most brilliant and experienced minds in ophthalmology. Soon we will see the beautiful result of all this work and dedication, and beyond the tremendous monetary satisfaction that success will bring, I think it is noteworthy to remember what it really is that we’re investing in here. AMD is the biggest cause of vision loss in advanced nations, I can think of few things worse than the loss of vision particularly as one enters their retirement years (a time supposed to be spent with family and celebrating a life well lived). Now here we have it, the biggest step forward in ophthalmology since anti-VEGF drugs were first approved. A drug that works in harmony with these existing treatments to deliver results to patients that have been desired for so long, but never achieved.Not just the temporary pausing of progression of the disease, but an actual and substantial improvement in their vision. Not to mention reduced visits to the doctor (something particularly important for older less mobile patients). As investors we have been essential in helping bring this innovative therapy to market, which is something I think we should be quite proud of. From simply supporting the company via the purchase of shares on the secondary market, to the more direct approach of supporting it via the purchase of new shares, we’ve played an important role alongside all the incredibly talented management, researchers, doctors etc.

Looking forward to the results, whereas with most biotech stocks I approach results with a degree of nervousness, here I definitely approach them with excitement. Between the existing results we have, observations from COAST, the unusually talented and experienced leadership time, it’s pretty easy to be confident that we are in the best possible position for success. We are on the verge of such a monumental innovation coming to market, and the shares remain so incredibly undervalued relative to the potential near term earnings. It’s certainly hard not to be excited about the future with OPT!